We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against firms ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

said the Drug Control Authority (DCA) agreed to give conditional approval to Spikevax, or what is commonly known as the Moderna Covid-19 vaccine.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ ... sparking fears among investors over his anti-vaccine stance. Despite his denial, Kennedy was said to be a prominent ...

This was significantly higher than the 7.035 million wasted vials of COVID-19 vaccines ... “The high rate of vaccine wastage, particularly for certain brands (including AstraZeneca, Janssen, Moderna ...

“We also observed a rapid, substantial, and durable expansion of new T cell clones related specifically to the vaccine.” Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early ...

Pfizer was down 1.8%, along with U.S. shares of its COVID-19 vaccine partner, BioNTech, which fell 2%. Moderna dropped 1.8% and Novavax slipped 2.3%. Shares of packaged food companies including ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ ... visibility into the sales trajectory of its respiratory vaccine business. Moderna earlier projected revenues for ...

In this article, we are going to take a look at where Moderna Inc. (NASDAQ:MRNA ... company has limited visibility into the sales trajectory of its respiratory vaccine business. Moderna earlier ...